Plenary Session - inactive due to federal service
A podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from University of California, San Francisco.
Tweet your feedback to @Plenary_Session or e-mail [email protected].
- Update frequency
- every 6 days
- Average duration
- 64 minutes
- Episodes
- 397
- Years Active
- 2018 - 2025
2.48 BONUS! Introduction to Malignant: How Bad Policy and Bad Evidence Harm People with Cancer
This week we have a BONUS episode for you! As a teaser to the forthcoming audiobook of "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer" by Dr. Vinay Prasad (our host), Audrey Tran…
00:20:31 |
Sat 25 Apr 2020
2.47 Remdesivir, Cloth Masks, & Incentives for COVID-19 Drug Development with Dr. Ameet Sarpatwari
This week we start with an in-depth monologue on various new developments surrounding COVID-19, specifically the new study in NEJM on the compassionate use of remdesivir as well as the CDC's advice f…
01:16:25 |
Thu 16 Apr 2020
2.46 Psychology Unearthed by COVID-19 Precautions & Polygenic Risk Score with Dr. Venk Murthy
This week we have a far-reaching monologue on COVID-19 and how people are reacting to the public health recommendations concerning COVID-19 (such as cancelling conferences and school, maintaining 6+ …
01:32:41 |
Sat 11 Apr 2020
2.45 Viral Spread of SARS-CoV-2, Rationing Resources, "Evidence Fiasco", & Classical Hematology Chat
This week we discuss several recent articles on the novel coronavirus (SARS-CoV-2) and COVID-19, specifically Dr. Siddhartha Mukherjee's article on the history and science of humanity's history with …
01:26:49 |
Wed 01 Apr 2020
2.44 ICU Management of COVID-19 with Dr. Benjamin Singer
This week we discuss management of COVID-19 in the intensive care unit with Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University. We discuss medications, PPE, venti…
00:37:57 |
Wed 25 Mar 2020
2.43 BONUS! Novel Coronavirus and the COVID-19 Response in Oregon with Dr. John Townes
This bonus episode is an interview from March 16, 2020 with Dr. John Townes, the Interim Head for the Division of Infectious Disease and the Medical Director for Infection Prevention and Control here…
00:41:59 |
Wed 18 Mar 2020
2.42 Quality-of-Life Measurement in Oncology, KnowYourTumor, & Question of the Week
This week we discuss two recent papers -- one we praise, one we condemn -- and then we turn to a question of the week with medical student Audrey Tran on self-improvement and "refining conviction". T…
01:08:25 |
Tue 17 Mar 2020
2.41 BONUS! Clinical Trials Part 2: Crossover and Control Arms
This BONUS lecture was a talk given to the Hematology/Oncology fellows here at Oregon Health & Science University. It's part two of a three-part series on clinical trials. This talk is on clinical tr…
00:51:40 |
Wed 11 Mar 2020
2.40 BEACON part 2, NALA, & Molecular Pathology and Next-Generation Sequencing with Dr. David Carr
This week we revisit BEACON! The authors of the BEACON study have responded to the Letter to the Editor our host Dr. Vinay Prasad submitted to the New England Journal of Medicine, and we share our th…
01:09:11 |
Thu 05 Mar 2020
2.39 Effectiveness of Newer-Generation Antidepressants with Dr. Michael Hengartner
Our guest this week is Dr. Michael Hengartner of the Zurich University of Applied Sciences. We interview him on his work studying the long-term consequences and effectiveness of newer-generation anti…
00:42:40 |
Thu 27 Feb 2020
2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali
We start this episode by diving deep into KEYNOTE-048, the randomized, open-label, phase 3 study of pembrolizumab alone or with chemotherapy v.s. cetuximab with chemotherapy for recurrent or metastat…
00:51:48 |
Wed 19 Feb 2020
2.37 Careerism, Presenting Abstracts, Twitter and the K-Index, & Classical Hematology Chat
We have a full slate for you this week! We discuss careerism in medicine, presenting abstracts at conferences, #MedTwitter, and Dr. Califf's opinions on the K-Index. We conclude the episode with our …
01:09:48 |
Fri 14 Feb 2020
2.36 Thought Leaders, NELSON, & Reliance on P Values in Cancer Trials with Dr. Sam Rubinstein
This week we discuss the concept of "thought leaders" and we examine the conclusions about volume CT screening for lung cancer from the NELSON trial. We end with an interview with Dr. Sam Rubinstein,…
00:59:11 |
Fri 07 Feb 2020
2.35 BONUS! How to Keep Up with the New Information in Medicine
This BONUS episode is the recording of a lecture given to medical students titled "How to Keep Up with the New Information in Medicine." It's a primer on the steps healthcare professionals need to ta…
01:00:17 |
Fri 31 Jan 2020
2.34 Red Light, Pola for DLBCL, Hem/Onc Question of the Week, & TAILORx with Dr. Ali Khaki
We have a variety of topics for you this week! We tackle red light therapy, polatuzumab olatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma; we have a hematology/oncology quest…
01:32:10 |
Fri 24 Jan 2020
2.33 Olaparib and POLO & the Classical Fallacies of Cancer Screening with Dr. H Gilbert Welch
This week we're treating you to a recording of the Grand Rounds lecture on overdiagnosis and cancer screening that Dr. H Gilbert Welch gave at Oregon Health & Science University on October 30, 2019. …
01:13:53 |
Wed 15 Jan 2020
2.32 BONUS! Clinical Trials Part 1: Thinking Better About Cancer Medicine
This BONUS lecture was a talk given to the Hematology/Oncology fellows here at Oregon Health & Science University. It's part one of a three-part series on clinical trials, titled "Thinking Better Abo…
00:53:10 |
Fri 10 Jan 2020
2.31 Listener Questions, Responsibility of Reviewers, & Duration of Response with Dr. Bishal Gyawali
This week we answer a few questions: the first is from Patreon backer, Harry Hong, on Kaplan-Meier curves. The second is from a student at Mount Sinai Medical School who reached out with some ethical…
00:40:09 |
Tue 07 Jan 2020
2.30 Questions from a Medical Student & Epidemiology with Dr. Ellie Murray
This week we return to our discussion of going after soft targets vs hard targets, but this time with a focus on how it applies to building a burgeoning career in medicine, in our segment Questions f…
01:47:54 |
Fri 03 Jan 2020
2.29 Time from Diagnosis to Treatment in AML and Real-World Data with Dr. Sherrie Aspinall
This week we wonder incredulously how this abstract from ASH titled "Time from diagnosis to treatment does not affect outcome in intensively treated patients with newly diagnosed acute myeloid leukem…
01:09:02 |
Fri 27 Dec 2019
Disclaimer: The podcast and artwork embedded on this page are the property of Vinay Prasad, MD MPH ([email protected]). This content is not affiliated with or endorsed by eachpod.com.